drugset / Trial / NCT00438399

Subject Preference for Scalp Psoriasis Treatment

NCT00438399

Phase 3 Completed 219 enrolled Galderma R&D
RandomizedCrossoverSingle-blindTreatment

Summary

The scalp is one of the most common affected sites in psoriatic patients as 79% of them have scalp involvement.It has also a psychological aspect with 31% of patients with scalp psoriasis indicating distress. Topical agents remain the mainstay of treatment for scalp psoriasis. However, they are not always ideal because they might be inconvenient and messy to use, stain or damage hair. The test shampoo, Clobetasol propionate Shampoo 0.05% (marketed in the USA under the tradename of Clobex®) was developed to provide the strongest available corticosteroid as a short-contact therapy in order to improve the chances of it being effective and reduce the potential for traditional side-effects. The objective of this study is to compare subject's overall preference between Clobetasol propionate shampoo 0.05% and three other topical corticosteroids in the treatment of moderate to severe scalp psoriasis.

Timeline

Start
2007-02
Primary completion
2008-01
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator clobetasol propionate Small molecule 0.05 % Topical

Indications